AN2 Therapeutics shares jump 14.91% premarket after announcing GSK collaboration and Gates Foundation funding for TB drug development.

AN2 Therapeutics (NASDAQ: ANTX) surged 14.91% in premarket trading following the announcement of a collaboration with GSK to develop boron-based LeuRS-inhibitors targeting tuberculosis (TB), supported by a third year of funding from the Gates Foundation. The partnership leverages AN2’s proprietary boron chemistry platform, which the company claims enables novel drug discovery for infectious diseases and oncology targets. CEO Eric Easom emphasized the potential of this approach to address unmet medical needs in TB, NTM lung disease, and solid-tumor oncology. The collaboration with GSK, a global biopharma leader, and continued Gates Foundation backing underscore the strategic and financial validation of AN2’s technology, likely driving investor optimism. The news aligns with the stock’s upward movement, reflecting confidence in the company’s pipeline and partnership potential.